{
	"kj8twg0qText": "Brintellix<span class=\"_ _0\"></span>® significant<span class=\"_ _1\"></span>ly impro<span class=\"_ _0\"></span>ved depressiv<span class=\"_ _2\"></span>e<span class=\"_ _1\"></span> <br><span class=\"ls11 ws2b\">sy<span class=\"_ _1\"></span>mptoms<span class=\"_ _1\"></span> in elderly pat<span class=\"_ _1\"></span>ients*<span class=\"_ _0\"></span><span class=\"fs2 ls0 v1\">1</span></span>",
	"kj8twg0rText": "Study Design",
	"kj8twg0sText": "Change in HAM-D<span class=\"fs13 ws56 v7\">24</span> total score in elderly pa<span class=\"_ _0\"></span>tients (≥65 years)<span class=\"fs13 v5\">1</span>",
	"kj8twg0tText": "Placebo (n=145)",
	"kj8twg0uText": "<div style=\"line-height: 1;\">*As measured by HAM-D; **p&lt;0.01; ***p&lt;0.001 vs.<span class=\"_ _0\" style=\"\"></span> placebo.<br>Fr<span class=\"_ _0\"></span>om a randomised, double-blind, placebo-contr<span class=\"_ _0\"></span>olled, duloxetine-refer<span class=\"_ _0\"></span>enced, fixed-dose study comparing the efficacy and safety of Brintellix® in elderly patients <br>(≥65 years) with MDD<span class=\"_ _0\"></span>. Estimated Hamilton R<span class=\"_ _0\"></span>ating Scale for Depression (24 items) HAM-D<span class=\"fsd ws1c v6\">24</span> total score from baseline to W<span class=\"_ _2\"></span>eek 8. Duloxetine was included as an active <br>reference for study validation,<span class=\"_ _0\"></span> not for comparison of effect size. N numbers relate to the intention to tr<span class=\"_ _0\"></span>eat (ITT) population.<br><span class=\"fsd ws1c\">†</span><span class=\"v6\">Brintellix® does not exhibit many of the side effects typical of SSRIs and SNRIs including sexual dysfunction and weight gain.</span><span class=\"fsd ws1c\">2-5</span><span class=\"v6\"> Side effects associated with Brintellix® <br style=\"\">were compar<span class=\"_ _0\"></span>ed with those of the SSRIs escitalopram and paroxetine and with those of the SNRI venlafaxine. F<span class=\"_ _0\"></span>or the 20 mg/day dose, an increase in tre<span class=\"_ _0\"></span>atment-emergent <br>sexual dysfunction was seen compared to placebo.<span class=\"_ _0\"></span> Please refer to the full Summary of Pr<span class=\"_ _0\"></span>oduct Characteristics or Pr<span class=\"_ _0\"></span>escribing Information for further information on safety <br>and tolerability; L<span class=\"_ _0\"></span>OCF<span class=\"_ _2\"></span>, last observation carried forward.</span></div>",
	"kj8twg0vText": "Brintellix® 5 mg (n=155)<span class=\"_ _40\"> </span><span class=\"fc1\">Duloxetine 60 mg (n=148) (active r<span class=\"_ _0\"></span>eference)</span>",
	"kj8twg0wText": "LOCF  ",
	"kj8twg0xText": "endpoint",
	"kj8twg0yText": "HAM-D<span class=\"fs1d ws57 v8\">24</span><span class=\"wsa\"> mean change  <span class=\"_ _f\"></span>from baseline</span>",
	"kj8twg0zText": "T<span class=\"_ _2\"></span>reatment week",
	"Brintellix_499ab4721b": "Text",
	"Brintellix_4968d708cd": "Text",
	"Brintellix_49d1958e9b": "Text",
	"Brintellix_4942a83df8": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: rgb(84, 122, 129); \">\n<font style=\"font-size: 25px;\">References</font>\n</span>",
	"Brintellix_490fca9331": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: #645e5e; display: block;\">\n<font style=\"font-size: 15px;\">\n\t<b>1.</b> Katona C at al. Int Clin Pyschopharmacol 2012;27:215-223.\n</font>\n</span>",
	"Brintellix_49e25c30fd": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: #645e5e; display: block;\">\n<font style=\"font-size: 15px;\">\n\t<b>2. </b>Brintellix<sup>®</sup> Summary of Product Characteristics. 2021.</font></span>",
	"Brintellix_491ae0e8f3": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: #645e5e; display: block;\">\n<font style=\"font-size: 15px;\">\n\t<b>3.</b> Cipralex<sup>®</sup> Summary of Product Characteristics. 2020. \n</font>\n</span>",
	"Brintellix_4966879b99": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: #645e5e; display: block;\">\n<font style=\"font-size: 15px;\">\n\t<b>4.</b> Effexor<sup>®</sup> Summary of Product Characteristics. 2020. \n</font>\n</span>",
	"Brintellix_49589bfe78": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: #645e5e; display: block;\">\n<font style=\"font-size: 15px;\">\n\t<b>5.</b> Seroxat<sup>®</sup> Summary of Product Characteristics. 2019.\n</font>\n</span>",
	"Brintellix_499eed28c4": "Text",
	"Brintellix_4981e6950f": "Text",
	"Brintellix_493c224484": "Text",
	"Brintellix_49be9a28ad": "<div style=\"font-family: serif;font-family: '2_VDWFON+AvenirNextLTPro-Demi';font-size: 13px;color: #4d7f86;\">Asian&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<span style=\"color: #fff;\"> Elderly</span>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Working&nbsp;population&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Anhedonia</div>"
}
